{"url_path":"/sec/ndra/8-k/2026-06-26/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **** Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-072268-index.html","accession_number":"0001213900-26-072268","cik":"0001681682","ticker":"NDRA","issuer_name":"ENDRA Life Sciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-072268-index.html","primary_entity_key":"0001681682","primary_entity_name":"ENDRA Life Sciences Inc."},"word_count":167,"has_tables":true,"body_markdown":"**Item 9.01.**** Financial Statements and Exhibits.**\n\n \n\n**Exhibit Number**\n \n**Description**\n\n2.1*\n \n[Agreement and Plan of Merger, dated as of June 25, 2026, by and among ENDRA Life Sciences Inc., Kruger Merger Sub LLC, Renergen Limited, Noble Africa LLC and ASP Isotopes Inc.](ea029523901ex2-1.htm)\n\n3.1\n \n[Form of A&R Certificate of Incorporation.](ea029523901ex3-1.htm)\n\n10.1\n \n[Form of Voting Agreement.](ea029523901ex10-1.htm)\n\n99.1**\n \n[Renergen Investor Presentation.](ea029523901ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*Certain schedules, annexes and exhibits to the Agreement and\nPlan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any such schedules,\nannexes and exhibits to the U.S. Securities and Exchange Commission upon request.\n\n \n\n**Furnished, not filed.\n\n** **\n\n7\n\n \n\n** **\n\n****\n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**ENDRA LIFE SCIENCES INC.**\n\n \n \n \n\nDate: June 26, 2026\nBy:\n/s/ Alexander Tokman\n\n \nName: \nAlexander Tokman\n\n \nTitle:\nChief Executive Officer\n\n \n\n8"}